MEDICREA Launches LIFETIME WARRANTY for its Patient-Specific UNiD™ Constructs at the 2016 Annual Meeting of the North American Spine Society (NASS)

LYON, France & NEW YORK–(BUSINESS WIRE)– The MEDICREA Group (Alternext Paris: FR0004178572 – ALMED), worldwide
leader pioneering the development and manufacture of personalized
analytical services and implant solutions for the treatment of complex
spinal conditions, announced today that the Company will implement a LIFETIME
WARRANTY on its patient-specific UNiD™ technology. The warranty will
cover all UNiD™ Thoracolumbar Rods, UNiD™ Cervical Rods and all
associated MEDICREA components implanted in the United States from
November 1, 2016.

Denys Sournac, President and CEO, stated, “Because of the overwhelmingly
positive results obtained in all of the 950 plus UNiD™ patient-specific
cases performed to date and our confidence in the science behind UNiD™
technology, MEDICREA is taking the extra step to warranty each
patient-specific implanted construct for the duration of the patient’s
life. This is a true testament to our belief that, by offering surgical
planning services with a patient-specific device, MEDICREA is
eliminating the inherent risks and associated costs to the healthcare
system that are created by manually bending a rod during surgery.”

Mr. Sournac continued, “While we know scientifically that sagittal
alignment is linked to patient outcomes, our experience with UNiD™ has
shown that applying the correct alignment to the rod, using proprietary
digital analysis organization that we have developed, may also be
directly linked to a reduction in surgical complications such as
mechanical failures and revision rate – something that was previously
only theorized.”

Currently, MEDICREA is the only company to propose a warranty on spinal
implants used in posterior spinal fusions, a procedure that more than
409,000 patients suffering from back pain undergo each year in the US
alone.¹ In complex spinal indications such as adult
deformity, research shows that nearly 1 in 10 patients who have
undergone spinal fusion experience symptomatic rod fracture.²
This poses a significant cost to the patient and the healthcare system
with the associated costs of readmission with reoperation totaling an
average of $80,000, a 70% cost increase from initial treatment.³
Further, these patients often require more than one revision surgery,
with each subsequent intervention becoming more and more complex leading
to a reported complication rate as high as 59%.⁴

The UNiD™ LIFETIME WARRANTY Program is offered as an affiliated benefit
of the UNiD™ Lab Premier Service, which includes a real-time support
team of biomechanical engineers supporting all pre-operative planning
and post-operative analytical services. MEDICREA will extend this
LIFETIME WARRANTY to all countries using UNiD™ technology, in order for
patients and healthcare providers to receive the maximum benefit of the
Company’s personalized services for complex spinal indications all over
the world. The LIFETIME WARRANTY proposed will fully cover UNiD™ Lab
services, patient-specific UNiD™ Rod replacement and all associated
MEDICREA implant components required to treat any patient undergoing a
revision surgery.

This announcement is released for the commencement of the North American
Spine Society (NASS) Annual Meeting in Boston. The scientific event held
from the 26th to the 29th of October is the largest of its kind bringing
together the global community of spinal surgeons, industry and
healthcare experts to present and exchange on the latest spinal
research. MEDICREA will host a Solution Showcase in the NASS Theater on
Thursday, October 27 at 12:30pm to present the early results showing
improved alignment and patient outcomes using UNiD™ patient-specific
planning and implant technology. The symposium is led by Dr. Andrew King
of New Orleans, LA and Dr. Themistocles Protopsaltis of New York, NY and
will feature MEDICREA’s innovative and growing portfolio of solutions
for complex spine, including PASS OCT^®, PASS LP^®
and LigaPASS^®.

Interested parties are encouraged to visit MEDICREA at NASS booth #943
or contact the company for more details about the UNiD™ Lab Premier
Service and UNiD™ LIFETIME WARRANTY Program.

References:

1. 2015 Thoracolumbar Procedures annually (409k). Millennium Research
   Group, Inc., “Traditional Thoracolumbar Implant Market, by Indication.”
2. Smith JS, Shaffrey CI, Klineberg E, et al. Prospective multicenter
   assessment of risk factors for rod fracture following surgery for
   adult spinal deformity. J Neurosurg Spine 21:994–1003, 2014.
3. McCarthy IM, Hostin RA, Ames CP, et al. Total hospital costs of
   surgical treatment for adult spinal deformity: an extended follow-up
   study. Spine J. 2014
4. Cho SK, Bridwell KH, Lenke LG, et al. Comparative analysis of clinical
   outcome and complications in primary versus revision adult scoliosis
   surgery. Spine (Phila. Pa. 1976). 2012

About MEDICREA (www.medicrea.com)

MEDICREA specializes in the design, manufacture, and distribution of
innovative proprietary technologies devoted exclusively to spinal
surgery. Operating in a $10 billion market, MEDICREA operates with 150
employees, including 45 at its MEDICREA USA Corp. subsidiary based in
New York City.

MEDICREA is the only company to offer personalized value-based
healthcare solutions to the global complex spine market. The Company has
driven innovation in Spine by focusing development on market-disrupting
technologies focused on patient outcomes, including the growing UNiD™
Technology Platform of Patient-Specific Implants and Analytical
Services, which received the first-ever FDA Clearance in November 2014
for a personalized spinal treatment modality.

MEDICREA has uniquely positioned itself outside of the traditional
implant manufacturer’s role in order to engage with each market player
as a collaborator, offering customized implants to patients,
personalized services to doctors and immediate cost-savings to
providers. By leveraging its proprietary software analysis tools with
big data technologies, MEDICREA is well-placed to improve the efficacy
of spinal care efficiency for all stakeholders in this market.

Connect with MEDICREA:
FACEBOOK
| INSTAGRAM
| TWITTER
| WEBSITE
| YOUTUBE

MEDICREA is listed on ALTERNEXT Paris
ISIN: FR 0004178572
– Ticker: ALMED

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161025006851/en/